Sugammadex Evidence-Based Utilization in Pediatric Surgical Patients    body {font-family: 'Open Sans', sans-serif;}

### Sugammadex Evidence-Based Utilization in Pediatric Surgical Patients

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  | TOF ≥ 2/4 twitches  
(vecuronium and rocuronium) | TOF ≤1/4 twitches or 1-2 post-tetanic twitches  
(vecuronium and rocuronium) | Emergency reversal  
(CICV Scenarios)  
(rocuronium only, within  
3 minutes of 1.2 mg/kg dose) |
| --- | --- | --- | --- |
| Ages 2-17 years old | 2 mg/kg (FDA-approved) | 4 mg/kg (FDA-approved) | 16 mg/kg (Off-label) |
| Ages <2 years old | 2-4 mg/mg (Off-label) | 2-4 mg/kg (Off-label) | 16 mg/kg (Off-label) |

  
  
Dosing is based on actual body weight. Sugammadex is not FDA-approved in patients under two or doses greater than 4 mg/kg.  
  
Still, current literature suggests the provided doses to be safe and effective with minimal to no increase in adverse effects.  
  
See “In-Depth Sugammadex in Pediatrics Literature Review” for more information.

**References:**  
Alonso, A., de Boer, H. D., & Booji, L. (2014). Reversal of rocuronium-induced neuromuscular block by sugammadex in neonates. _European Journal of Anaesthesiology_ , _31_ , 163.  
https://tinyurl.com/3b3ab2vz  
  
Alsuhebani, M., Sims, T., Hansen, J. K., Hakim, M., Walia, H., Miller, R., Tumin, D., & Tobias, J. D. (2020). Heart rate changes following the administration of sugammadex in children: A prospective, observational study. _Journal of Anesthesia_ , _34_ , 238–242.  
https://doi.org/10.1007/s00540-019-02729-y  
  
Cardenas, V. H., & Gonzalez, F. D. (2013). Sugammadex in the neonatal patient. _Columbian Journal of Anesthesiology_ , _41_ (2), 171–174.  
https://doi.org/10.1016/j.rcae.2013.02.003  
  
Franz, A. M., Chiem, J., Martin, L. D., Rampersad, S., Phillips, J., & Grigg, E. B. (2019). Case series of 331 cases of sugammadex compared to neostigmine in patients under 2 years of age.  
_Pediatric Anesthesia_ , _29_ (6), 591–596. https://doi.org/10.1111/pan.13643  
  
Langley, R. J., McFadzean, J., & McCormack, J. (2016). The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex.  
_Paediatric Anaesthesia_ , _26_ (1), 109–111. https://doi.org/10.1111/pan.12789  
  
Matsui, M., Konishi, J., Suzuki, T., Sekijima. C., Miyazawa, N., & Yamamoto, S. (2019) Reversibility of rocuronium-induced deep neuromuscular block with sugammadex in infants and children--- A randomized study. _J-stage, 42_ (10), 1637-1640. https://doi.org/10.1248/bpb.b19-00044  
  
Ozmete, O., Bali, C., Cok, O. Y., Turk, H. E., Ozyilkan, N. B., Civi, S., & Aribogan, A. (2016). Sugammadex given for rocuronium-induced neuromuscular blockade in infants: A retrospective study. _Journal of Clinical Anesthesia_ , _35_ , 497–501.  
https://doi.org/10.1016/j.jclinane.2016.08.040  
  
Saber, H., Mousa, S. A., AbouRezk, A. R., & Zaglool, A. (2021). Recovery profile of sugammadex versus neostigmine in pediatric patients undergoing cardiac catheterization: A randomized double-blind study. _Anesthesia, Essays and Researches_ , _15_ (3), 272–278.  
https://doi.org/10.4103/aer.aer\_139\_21  
  
Sari, S., Tasdemir, B., Sözkısacık, S., & Gürsoy, F. (2013). Side effects of sugammadex use in pediatric patients. _Journal of Clinical and Experimental Investigations_ , _4_ (3), 265–268.  
https://doi.org/10.5799/ahinjs.01.2013.03.0281  
  
Turk, H. S., Kilinc, L., Sayin, P., & Oba, S. (2019). Retrospective study of the restoration of neuromuscular blockage with sugammadex in newborns who used rocuronium. _Southern Clinics of Istanbul Eurasia_ , _30_ (2), 163–166. https://doi.org/10.14744/scie.2019.05025  
  
Voss, T., Wang, A., DeAngelis, M., Speek, M., Saldien, V., Hammer, G. B., Wrishko, R., & Herring, W.J. (2022). Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results  
from a phase IV randomized study. _Pediatric Anesthesia_ , _32_ (3), 436–445.  
https://doi.org/10.1111/pan.14370  
  
Wakimoto, M., Burrier, C., & Tobias, J. D. (2018). Sugammadex for rapid intraoperative reversal of neuromuscular blockade in a neonate. _Journal of Medical Cases_ , _9_ (12), 400–402.  
https://doi.org/10.14740/jmc3213  
  
Yost, S. (2021). _Clinical review_ . U.S. Food and Drug Administration.  
https://www.fda.gov/media/152066/download